Mustafa Neamatallah1, Mahmoud El-Bendary2, Hatem Elalfy2, Tarek Besheer2, Mohamed Abd El-Maksoud2, Dina Elhammady2, Sally Abed2, Mohamed Elegezy2, Lamiaa Kandeel3, Dalia Eldeib4, Naser Mousa2, Mohamed Abd El-Hafeez5, Abdel-Hady El-Gilany6, Gamal Esmat7. 1. Medical Biochemistry Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 2. Tropical Medicine and Hepatology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 3. Ministry of Health, Sherbeen General Hospital, Sherbeen city, Egypt. 4. Biochemistry department, Faculty of Science, Mansoura University, Mansoura, Egypt. 5. Microbiology Department, Faculty of Science, Mansoura University, Mansoura, Egypt. 6. Public Health Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 7. Tropical Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Abstract
Background and Aims: Genetic polymorphisms of Toll-like receptors (TLRs) have been proposed to affect susceptibility to HCV infection and progression to end-stage liver disease. This study was conducted to clarify the association of SNPS of TLR2 and TLR4 with clinical outcome of hepatitis C, response to treatment and development of HCC. Methods: The current study examined 3295 individuals from 725 families that were categorized into groups comprising chronic HCV (CH), spontaneous viral clearance (SC) and control subjects. Treated patients were classified into responders (RT) and non-responders (NRT). In addition, patients with liver cirrhotic (LC), and hepatocellular carcinoma (HCC) were also included. All subjects were genotyped for five single nucleotide polymorphisms (SNPs) of TLR2 and four SNPs of TLR4 and their haplotypes using allelic discrimination real-time PCR. Results: Results demonstrated strong association with allele A of rs13105517 of TLR2 and allele C of rs10116253 of TLR4 with CH in comparison to SC group. However, The peak of risk of HCC was observed with allele C of rs3804099 of TLR2 and C allele of rs10116253 TLR4 (p < 0.001).A strong association was found with allele T of rs1816702 of TLR2 and allele A of rs5030728 of TLR4 in non responder group in comparison to responders (p < 0.001). Haplotypes CAGT of TLR4 and ATAC of TLR2 showed significant association with CH and HCC groups in comparison to other groups.Conclusions: This study shows an association of minor alleles of TLR2 and TLR4 with outcome of HCV infection, response to therapy and development of HCC in cirrhotic patients.
Background and Aims: Genetic polymorphisms of Toll-like receptors (TLRs) have been proposed to affect susceptibility to HCV infection and progression to end-stage liver disease. This study was conducted to clarify the association of SNPS of TLR2 and TLR4 with clinical outcome of hepatitis C, response to treatment and development of HCC. Methods: The current study examined 3295 individuals from 725 families that were categorized into groups comprising chronic HCV (CH), spontaneous viral clearance (SC) and control subjects. Treated patients were classified into responders (RT) and non-responders (NRT). In addition, patients with liver cirrhotic (LC), and hepatocellular carcinoma (HCC) were also included. All subjects were genotyped for five single nucleotide polymorphisms (SNPs) of TLR2 and four SNPs of TLR4 and their haplotypes using allelic discrimination real-time PCR. Results: Results demonstrated strong association with allele A of rs13105517 of TLR2 and allele C of rs10116253 of TLR4 with CH in comparison to SC group. However, The peak of risk of HCC was observed with allele C of rs3804099 of TLR2 and C allele of rs10116253TLR4 (p < 0.001).A strong association was found with allele T of rs1816702 of TLR2 and allele A of rs5030728 of TLR4 in non responder group in comparison to responders (p < 0.001). Haplotypes CAGT of TLR4 and ATAC of TLR2 showed significant association with CH and HCC groups in comparison to other groups.Conclusions: This study shows an association of minor alleles of TLR2 and TLR4 with outcome of HCV infection, response to therapy and development of HCC in cirrhoticpatients.
Authors: M Neamatallah; M S Serria; M El-Bendary; A-H El-Gilany; A Alhawarey; S Abed; Y A Setate; O A Ammar Journal: Br J Biomed Sci Date: 2022-03-23 Impact factor: 2.432
Authors: Asmaa M Elbrolosy; Naglaa S Elabd; Gamalat A ElGedawy; Mai Abozeid; Mervat Abdelkreem; Belal Montaser; Emad M Eed; Moamena S Elhamouly Journal: Clin Exp Med Date: 2022-02-04 Impact factor: 3.984
Authors: Laura Elena Córdova-Dávalos; Alicia Hernández-Mercado; Claudia Berenice Barrón-García; Augusto Rojas-Martínez; Mariela Jiménez; Eva Salinas; Daniel Cervantes-García Journal: Virus Genes Date: 2022-09-09 Impact factor: 2.198